Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis

MLA

Mohamed H. Mahmoud, et al. “Interference With the AMPKα/MTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis.” Frontiers in Pharmacology, vol. 12, Aug. 2021. EBSCOhost, https://doi.org/10.3389/fphar.2021.719984.

APA

Mohamed H. Mahmoud, Amir Mohamed Abdelhamid, Noha A. Amin, Ahmed Gaafar Ahmed Gaafar, Sameh Saber, Helal F Hetta, Naglaa A. Gobba, Eman El-Ahwany, Hanan Eissa, Gaber El-Saber Batiha, Eslam E. Abd El-Fattah, & Mahmoud E. Youssef. (2021). Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.719984

Chicago

Mohamed H. Mahmoud, Amir Mohamed Abdelhamid, Noha A. Amin, Ahmed Gaafar Ahmed Gaafar, Sameh Saber, Helal F Hetta, Naglaa A. Gobba, et al. 2021. “Interference With the AMPKα/MTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis.” Frontiers in Pharmacology 12 (August). doi:10.3389/fphar.2021.719984.